[Pharmacological bases of therapy with 5-ASA].
Beltrán
B
B
Departamento de Farmacología, Facultad de Medicina y Odontología, Universidad de Valencia.
Martínez-Cuesta
M A
MA
Calatayud
S
S
Hinojosa
J
J
Esplugues
J V
JV
D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000493:pharmacokinetics; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D003692:Delayed-Action Preparations; D005260:Female; D005609:Free Radicals; D006801:Humans; D008297:Male; D019804:Mesalamine; D013427:Sulfapyridine / Q000493:pharmacokinetics / Q000627:therapeutic use; D012460:Sulfasalazine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
D000636:Aminosalicylic Acids; D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D005609:Free Radicals; D012460:Sulfasalazine; D019804:Mesalamine; D013427:Sulfapyridine